Aim: The intention of this investigation was to develop Pemetrexed Diacid (PTX)-loaded
gelatine-cloisite 30B (MMT) nanocomposite for the potential oral delivery of PTX and the in vitro, and
ex vivo assessment.
Background: Gelatin/Cloisite 30 B (MMT) nanocomposites were prepared by blending gelatin with
MMT in aqueous solution.
Methods: PTX was incorporated into the nanocomposite preparation. The nanocomposites were
investigated by Fourier Transmission Infra Red Spectroscopy (FT-IR), Differential Scanning
Calorimetry (DSC), Scanning Electron Microscope (SEM) X-Ray Diffraction (XRD) and Confocal
Laser Microscopy (CLSM). FT-IR of nanocomposite showed the disappearance of all major peaks
which corroborated the formation of nanocomposites. The nanocomposites were found to have a
particle size of 121.9 ± 1.85 nm and zeta potential -12.1 ± 0.63 mV. DSC thermogram of drug loaded
nanocomposites indicated peak at 117.165 oC and 205.816 oC, which clearly revealed that the drug has
been incorporated into the nanocomposite because of cross-linking of cloisite 30 B and gelatin in the
presence of glutaraldehyde.
Results: SEM images of gelatin show a network like structure which disappears in the nanocomposite.
The kinetics of the drug release was studied in order to ascertain the type of release mechanism. The
drug release from nanocomposites was in a controlled manner, followed by first-order kinetics and the
drug release mechanism was found to be of Fickian type.
Conclusion: Ex vivo gut permeation studies revealed 4 times enhancement in the permeation of drug
present in the nanocomposite as compared to plain drug solution and were further affirmed by CLSM.
Thus, gelatin/(MMT) nanocomposite could be promising for the oral delivery of PTX in cancer therapy
and future prospects for the industrial pharmacy.